Clinical Trial Update: Intravitreal Topotecan for Prevention or Treatment of Proliferative Vitreoretinopathy in Retinal Detachment [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating intravitreal topotecan to prevent or treat proliferative vitreoretinopathy in rhegmatogenous retinal detachment; the study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Proliferative Vitreoretinopathy
• Rhegmatogenous Retinal Detachment

Drugs mentioned

• Topotecan (topotecan)

Snippet

Sponsor: Unity Health Toronto | Conditions: Retinal Detachment Rhegmatogenous, Proliferative Vitreoretinopathy | Phase 2 | Status: NOT_YET_RECRUITING